Lercanidipine Clonmel (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Clonmel, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by relaxing vascular smooth muscle and lowering blood pressure.

GNH USA supplies Lercanidipine Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker used to manage high‑blood‑pressure disorders.

Hypertension: lowers systemic blood pressure in patients with primary hypertension. Essential hypertension: provides sustained blood‑pressure control in adults. Isolated systolic hypertension: reduces systolic pressure in elderly patients.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Palpitations - Fatigue

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Myocardial infarction - Hepatic dysfunction - Stevens‑Johnson syndrome - Atrioventricular block

When prescribing Lercanidipine, clinicians should consider several safety measures.

Blood pressure monitoring: check baseline and periodic readings. Hepatic impairment: use with caution in patients with liver disease. Elderly patients: start at lower dose and monitor for hypotension. Concomitant antihypertensives: assess for additive blood‑pressure lowering. Sudden discontinuation: avoid abrupt stop to prevent rebound hypertension. Store at room temperature: keep in original packaging, protect from moisture and light.

Lercanidipine can interact with other medicines, affecting its plasma levels or blood‑pressure response.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase Lercanidipine concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may substantially reduce therapeutic effect. - Grapefruit juice (large amounts): can elevate drug exposure and risk of hypotension.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause additive hypotensive effect. - Diuretics: increase risk of electrolyte imbalance and orthostatic hypotension. - NSAIDs: may attenuate blood‑pressure‑lowering efficacy. - Simvastatin: increased risk of myopathy due to shared metabolism.